Franssen A M, Rolland R, Chadha D R, Willemsen W N, Vemer H M
Eur J Obstet Gynecol Reprod Biol. 1986 Dec;23(5-6):379-86. doi: 10.1016/0028-2243(86)90173-5.
Luteinising hormone-releasing hormone agonist (Buserelin) therapy administered for a period of 6 months in 4 patients with longstanding, severe, danazol-resistant endometriosis, was found to be effective in reducing all complaints related to endometriosis. From 2 weeks on, nearly half of the E2 determinations were below the sensitivity level of the assay, while the other values were predominantly in the range of the early follicular phase. Side effects associated with the induced hypoestrogenemia were mild and well tolerated. After six months of follow-up without treatment, one patient who desired pregnancy conceived shortly after cessation of therapy and one patient showed lasting amelioration of her complaints. The symptoms relapsed in the other two, possibly due to inadequate dose and/or duration of treatment.
对4例患有长期、严重、对达那唑耐药的子宫内膜异位症患者给予促黄体生成素释放激素激动剂（布舍瑞林）治疗6个月，发现该治疗在减轻所有与子宫内膜异位症相关的症状方面有效。从第2周起，近一半的雌二醇测定值低于检测方法的灵敏度水平，而其他值主要处于卵泡早期范围。与诱导的低雌激素血症相关的副作用轻微且耐受性良好。在未经治疗的6个月随访后，1例希望怀孕的患者在治疗停止后不久受孕，1例患者的症状持续改善。另外2例患者症状复发，可能是由于治疗剂量和/或疗程不足。
